Search results for " Pharmaceutic"

showing 10 items of 865 documents

<p>Future perspectives of anticholinergics for the treatment of asthma in adults and children</p>

2019

Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinic…

medicine.medical_specialtymedicine.drug_classPsychological intervention030204 cardiovascular system & hematologyAsthma managementPlacebo03 medical and health sciences0302 clinical medicineAnticholinergicMedicinePharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsDisease management (health)Intensive care medicineAsthmaChemical Health and Safetybiologybusiness.industryGeneral MedicineLamabiology.organism_classificationmedicine.diseaserespiratory tract diseasesClinical trialbusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct

Managing Persistent Hypoxemia: what is new?

2017

Mechanical ventilation is the standard life-support technique for patients with severe acute respiratory failure. However, some patients develop persistent and refractory hypoxemia because their lungs are so severely damaged that they are unable to respond to the application of high inspired oxygen concentration and high levels of positive end-expiratory pressure. In this article, we review current knowledge on managing persistent hypoxemia in patients with injured lungs.

medicine.medical_specialtymedicine.medical_treatmentPhysiologyReviewmechanical ventilationGeneral Biochemistry Genetics and Molecular BiologyHypoxemia03 medical and health sciences0302 clinical medicineRefractorysevere acute respiratory failuremedicineAcute respiratory failureIn patientGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineMechanical ventilationInspired oxygen concentrationhypoxemiaGeneral Immunology and Microbiologypersistent hypoxemiabusiness.industry030208 emergency & critical care medicineGeneral MedicineArticlesrespiratory tract diseases030228 respiratory systemRespiratory Problems in Critical Caremedicine.symptombusinessF1000Research
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Does anti-inflammatory drugs modify the severe odontogenic infection prognosis? A 10-year’s experience

2020

Background Numerous biochemical datas support the noxious role of anti-inflammatory drugs on immune response. Those observations are often put forward for unfavorable evolution of odontogenic infection but has never been really proven in clinic. The aim of this study is to try to clarify this role based on the collection of the clinical course of odontogenic infections over a 10-year analysis period. Material and Methods The investigators implemented a prospective observational study. The sample was composed of patients managed between January 2004 and December 2014 for severe odontogenic infection based on three criteria: hospital admission, intravenous antibiotic therapy, tooth extraction…

medicine.medical_specialtytumorErythemamedicine.drug_classMESH: Pharmaceutical PreparationsPopulationAnti-Inflammatory AgentsPaincarcinomaMESH: Prognosislip03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASOdontogenic infectioncystUnivariate analysiseducation.field_of_studyMESH: Humansbusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistrymedicine.diseasePrognosisMESH: Anti-Inflammatory Agents Non-SteroidalOtorhinolaryngologyPharmaceutical PreparationsMESH: Anti-Inflammatory AgentsPropensity score matching[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCorticosteroidSurgeryObservational studyMESH: Painmedicine.symptomOral SurgerybusinessOdynophagianeoplasm
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Evaluation of Flavonoid Derivative and Doxorubicin Effects in Lung Cancer Cells (A549) Using Differential Pulse Voltammetry Method.

2018

Purpose: Electrochemical measurements have prompted the progress as a consequence of their affectability, cost-affectivity and comparatively short examination time. The aim of this study was the fast evaluation of the effect of chemotherapy compounds on the viability of lung cancer cells (A549) via electrochemical methods. Methods: Cyclic voltammetry (CV) was used as a primary method to distinguish between electrochemical behavior of normal and lung cancer cells. Differential pulse voltammetry (DPV) was employed as a complementary analyses method for the impact of doxorubicin (DOX) and Flavonoid modified drug (FMD) (US patent Application number: 62548886) on Lung cancer cells. Results: Only…

medicine.medical_treatmentFlavonoidPharmaceutical SciencePharmacology01 natural sciences0404 agricultural biotechnologyLung neoplasmsElectrochemistrymedicineDoxorubicinGeneral Pharmacology Toxicology and PharmaceuticsLung cancerVoltammetrychemistry.chemical_classificationChemotherapylcsh:RM1-950010401 analytical chemistry04 agricultural and veterinary sciencesmedicine.disease040401 food science0104 chemical scienceslcsh:Therapeutics. PharmacologychemistryDoxorubicinCancer cellVoltammetryDifferential pulse voltammetryCyclic voltammetryResearch Articlemedicine.drugAdvanced pharmaceutical bulletin
researchProduct

Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in…

2023

Pancreatic ductal adenocarcinoma (PDAC) is one of the main aggressive types of cancer, characterized by late prognosis and drug resistance. Among the main factors sustaining PDAC progression, the alteration of cell metabolism has emerged to have a key role in PDAC cell proliferation, invasion, and resistance to standard chemotherapeutic agents. Taking into account all these factors and the urgency in evaluating novel options to treat PDAC, in the present work we reported the synthesis of a new series of indolyl-7-azaindolyl triazine compounds inspired by marine bis-indolyl alkaloids. We first assessed the ability of the new triazine compounds to inhibit the enzymatic activity of pyruvate de…

nortopsentin analoguespancreatic ductal adenocarcinoma (PDAC); nortopsentin analogues; antitumor activity; pyruvate dehydrogenase kinases (PDKs); cytotoxic activity; metabolic alterations; ligand-based homology modeling; KRASDrug Discoveryligand-based homology modelingKRASPharmaceutical Scienceantitumor activitymetabolic alterationspancreatic ductal adenocarcinoma (PDAC)Pharmacology Toxicology and Pharmaceutics (miscellaneous)cytotoxic activitypyruvate dehydrogenase kinases (PDKs)
researchProduct

Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors

2012

Herein we report the synthesis of a set of constrained peptidomimetics endowed with an electrophilic vinyl ester warhead and structurally related to a previously identified lead compound, a potent and irreversible inhibitor of falcipain-2 (FP-2). FP-2 is the main hemoglobinase of the malaria parasite P. falciparum. The new compounds were evaluated for their inhibition against FP-2, and the results were rationalized on the basis of docking experiments. These studies underscore the pivotal role of both the ester function at the P1' site and the trifluoromethyl group of the P3 side chain in determining the correct orientation of the Michael acceptor warhead in the catalytic site, and as a cons…

peptidomimeticdMolecular modelPeptidomimeticStereochemistryPlasmodium falciparumVinyl esterBiochemistrycysteine proteasesfalcipain-2 inhibitorsAntimalarialschemistry.chemical_compoundCatalytic DomainDrug DiscoverySide chainHumansEnzyme InhibitorsMalaria FalciparumGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyTrifluoromethylOrganic Chemistrydocking studiescysteine proteases; peptidomimeticd; docking studies; falcipain-2 inhibitorsMolecular Docking SimulationCysteine EndopeptidaseschemistryDocking (molecular)Michael reactionMolecular MedicinePeptidomimeticsLead compoundChemMedChem
researchProduct

Pharmacy Practice and Education in Latvia

2018

Pharmacies in Bulgaria have a monopoly on the dispensing of medicinal products that are authorized in the Republic of Bulgaria, as well as medical devices, food additives, cosmetics, and sanitary/hygienic articles. Aptekari (pharmacists) act as responsible pharmacists, pharmacy owners, and managers. They follow a five year Masters of Science in Pharmacy (M.Sc. Pharm.) degree course with a six month traineeship. Pomoshnik-farmacevti (assistant pharmacists) follow a three year degree with a six month traineeship. They can prepare medicines and dispense OTC medicines under the supervision of a pharmacist. The first and second year of the M.Sc. Pharm. degree are devoted to chemical sciences, ma…

pharmacymedicine.medical_specialtyHigher educationPharmacistlcsh:RS1-441PharmacyArticlelcsh:Pharmacy and materia medicapharmacy; education; practice; Latvia; European Unionmedicinemedia_common.cataloged_instancePharmacology (medical)BulgarianEuropean UnionGeneral Pharmacology Toxicology and PharmaceuticsEuropean unionmedia_commoneducationbusiness.industryRedactionLatviapracticelanguage.human_languagePharmaceutical careFamily medicinelanguagePharmacy practicebusinessPharmacy
researchProduct